POET Technologies Inc. — 2022 Form 20-F Summary
Reporting period: Fiscal year ended December 31, 2022. This is an annual report, not a standalone fourth-quarter filing. Unless stated otherwise, amounts are in U.S. dollars. Financial statements are prepared under IFRS as issued by the IASB.
Business context
POET designs and develops photonic integration products based on its Optical Interposer platform, targeting data-center communications, telecom, AI-related light sources and other applications. It is transitioning from technology development to product development and uses a “fab-light” model, relying on external manufacturing and its China-based joint venture, Super Photonics Xiamen (SPX), with Sanan IC.
Financial performance and position
| Metric | 2022 | 2021 |
|---|---|---|
| Revenue | $552,748 | $209,100 |
| Operating loss | $19,710,266 | $17,011,556 |
| Net loss | $21,036,690 | $15,669,093 |
| Basic and diluted loss per share | $0.57 | $0.45 |
| Cash used in operating activities | $12,325,910 | $11,233,293 |
| Cash and cash equivalents at year-end | $9,229,845 | $14,941,775 |
| Working capital | $5,751,101 | $19,865,170 |
| Total assets | $15,390,453 | $27,153,977 |
| Total liabilities | $3,945,405 | $2,182,230 |
| Research and development expense | $10,746,743 | $8,165,128 |
| Capital expenditures | $3,074,037 | $930,882 |
Revenue was primarily non-recurring engineering services; the filing does not report material product-sales revenue. Margins are not meaningful at this revenue scale. POET reported no convertible debentures at year-end; liabilities included $279,263 of lease obligations and a $29,520 COVID-related government loan. The company had an accumulated deficit of $194,023,660.
Material changes versus 2021
- Net loss widened by approximately 34%, while operating expenses rose about 18%. R&D expense increased 32%, which management attributed to the shift toward product development, engineering hires, supplier engagement and qualification work.
- Revenue increased by $343,648 as the company provided NRE services to multiple customers, but remained small relative to expenses.
- Operating cash outflow increased by about $1.1 million. Cash and short-term investments fell from $21,308,603 at the end of 2021 to $9,229,845 in cash at the end of 2022; the 2021 short-term investments matured during 2022.
- SPX-related results changed from a net gain in 2021 to a net loss impact of $1,465,006 in 2022: POET recognized $3,211,993 of SPX losses and a $1,746,987 gain on contributed intellectual property. The SPX investment carrying value was zero at year-end.
- POET completed a 10-for-1 share consolidation and began Nasdaq trading under “POET” in March 2022. It raised $3,184,332 gross in a December 2022 private placement.
Liquidity, outlook and risks
Going concern: Management’s cash-flow forecast showed insufficient cash to meet minimum expenditure commitments without additional funding. The filing states that substantial doubt exists about the company’s ability to continue as a going concern for the next 12 months. Marcum LLP’s financial-statement audit includes a going-concern explanatory paragraph, although its opinions on the financial statements and internal controls were unqualified. Management described warrant exercises, a strict budget and the December financing as funding measures, but said future financing was not assured. The filing also says the company had a reasonable expectation it could manage its finances; investors should weigh this against the forecast and auditor disclosure.
After year-end, POET reported receiving $5,475,102 from warrant exercises between January 23 and March 22, 2023. Management expected to invest a further $10 million in product development in 2023, had an approved 2023 capital budget of $811,000, and expected volume production of customer-specific optical engines and packaged light sources to begin in 2023, with high-volume ramp later in 2023 and into 2024. These are expectations, not assured outcomes.
Key execution risks include customer qualification and design wins, product reliability and acceptance, manufacturing scale-up and dependence on limited suppliers. Additional risks include competition, potential equity dilution, intellectual-property protection, and geopolitical, governance and operating risks associated with the China joint venture. The filing describes COVID-related supplier backlogs that had delayed some development objectives by four to six months or longer.
Important facts for investors to verify
- Whether subsequent warrant exercises and other financing provide adequate liquidity, and how long available cash can fund operations and planned development.
- Progress of customer qualification, design wins, product revenue and the anticipated 2023–2024 production ramp.
- SPX’s actual funding and operating performance, the basis for POET’s reported ownership percentage and equity-method treatment, and the implications of its investment carrying value being zero.
- Potential dilution from outstanding options and warrants, future financing needs and the company’s ability to raise capital on acceptable terms.
- The full audited financial statements and going-concern disclosures; the filing reports effective disclosure controls and internal control over financial reporting as of December 31, 2022.